Qian Liu , Xinru Liu , Le Chang , Huimin Ji , Huizhen Sun , Ying Yan , Junjie Xu , Lunan Wang
{"title":"Optimizing HIV testing: Comparing diagnostic signatures and assay performance in ART-treated and general screening populations","authors":"Qian Liu , Xinru Liu , Le Chang , Huimin Ji , Huizhen Sun , Ying Yan , Junjie Xu , Lunan Wang","doi":"10.1016/j.cca.2025.120207","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Accurate and early HIV detection is crucial for improving outcomes and controlling transmission. This study compares HIV marker patterns and evaluates detection assay performance in general screening and ART-treated populations to enhance diagnostic accuracy and public health.</div></div><div><h3>Methods</h3><div>A total of 196 blood donor samples that were initially reactive in blood center screening were collected across 17 provinces in China, along with 126 ART samples from people living with HIV (PLWH). HIV RNA, Ag/Ab, and western blot were conducted in both groups. CD4 T cell counts were assessed in PLWH. The performance of two antigen detection kits (Wantai, Livzon) and eight Ag/Ab kits (Roche, Abbott, KHB, InTec, Wantai, Livzon, Murex, Bio-rad) were evaluated.</div></div><div><h3>Results</h3><div>In the ART group, all samples were Ag/Ab positive, with 32.5 % (41/126) having undetectable viral loads; NAT-positive samples showed a higher rate of complete bands in western blot compared to NAT-negative group (42.5 % vs 15.4 %, <em>P</em> = 0.021), while p17, p39, and p31 bands were often absent. 90.8 % (178/196) of blood donors were NAT-positive and Ag/Ab-positive. 4.6 % (9/196) of blood donors were NAT-positive but Ag/Ab-negative, these samples were also tested as NAT-only reactive in screening at blood centers, often showing only a p24 band or negative result in WB, indicating early acute infection. 3.6 % (7/196) of blood donors were confirmed as NAT-negative but Ag/Ab-positive, hinting that a small group on ART might attempt to donate blood. HIV serological kits showed 100 % positivity in the ART group. Fourth-generation kits, particularly the Roche Ag/Ab kit, showed the highest sensitivity (95.2 %) for NAT-positive donors.</div></div><div><h3>Discussion</h3><div>This study highlights critical differences in HIV detection between ART-treated individuals and general screening populations, emphasizing the need for tailored diagnostic strategies to ensure blood transfusion safety.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"570 ","pages":"Article 120207"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125000865","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Accurate and early HIV detection is crucial for improving outcomes and controlling transmission. This study compares HIV marker patterns and evaluates detection assay performance in general screening and ART-treated populations to enhance diagnostic accuracy and public health.
Methods
A total of 196 blood donor samples that were initially reactive in blood center screening were collected across 17 provinces in China, along with 126 ART samples from people living with HIV (PLWH). HIV RNA, Ag/Ab, and western blot were conducted in both groups. CD4 T cell counts were assessed in PLWH. The performance of two antigen detection kits (Wantai, Livzon) and eight Ag/Ab kits (Roche, Abbott, KHB, InTec, Wantai, Livzon, Murex, Bio-rad) were evaluated.
Results
In the ART group, all samples were Ag/Ab positive, with 32.5 % (41/126) having undetectable viral loads; NAT-positive samples showed a higher rate of complete bands in western blot compared to NAT-negative group (42.5 % vs 15.4 %, P = 0.021), while p17, p39, and p31 bands were often absent. 90.8 % (178/196) of blood donors were NAT-positive and Ag/Ab-positive. 4.6 % (9/196) of blood donors were NAT-positive but Ag/Ab-negative, these samples were also tested as NAT-only reactive in screening at blood centers, often showing only a p24 band or negative result in WB, indicating early acute infection. 3.6 % (7/196) of blood donors were confirmed as NAT-negative but Ag/Ab-positive, hinting that a small group on ART might attempt to donate blood. HIV serological kits showed 100 % positivity in the ART group. Fourth-generation kits, particularly the Roche Ag/Ab kit, showed the highest sensitivity (95.2 %) for NAT-positive donors.
Discussion
This study highlights critical differences in HIV detection between ART-treated individuals and general screening populations, emphasizing the need for tailored diagnostic strategies to ensure blood transfusion safety.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.